Earnings ·
Imunon, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $2.8 million, or…
IMNNImunon, Inc.
Imunon, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $2.8 million, or $0.54 per share, compared to a net loss of $2.7 million in the prior year period. Operating expenses remained flat at $2.8 million, with research and development costs rising to $1.5 million from $1.2 million, while general and administrative expenses decreased to $1.3 million from $1.5 million. The company raised $10 million through a corporate development transaction in June 2026, consisting of preferred stock and secured promissory notes. Clinically, enrollment in the pivotal Phase 3 OVATION 3 trial for IMNN-001 is exceeding forecasts, with completion expected by early 2029. Imunon operates as a clinical-stage biotechnology company developing DNA-mediated immunotherapies for cancer treatment.